Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01367756
A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01365403
A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 276
- Registration Number
- NCT01364012
- Locations
- 🇨🇳
Beijing Hospital of Ministry of Health; Hematology, Beijing, China
🇨🇳General Hospital of Chinese PLA; Department of Hematology, Beijing, China
🇨🇳Beijing Chest Hospital; Oncology Department, Beijing, China
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01363986
A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01363999
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT01362062
- Locations
- 🇮🇳
Excel Center, Guwahati, India
🇮🇳Sir Gangaram Hospital, New Delhi, Delhi, India
🇮🇳Healing Touch City Clinic, Chandigarh, India
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4804
- Registration Number
- NCT01358877
- Locations
- 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: RO5429083
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 65
- Registration Number
- NCT01358903
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01358929
An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 156
- Registration Number
- NCT01358942